Is it time to revisit MRD’s role in relapse detection?
A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD) in hematologic malignancies.
Leukemia
Lymphoma
Multiple Myeloma
News
Myeloproliferative Neoplasms
Polycythemia Vera
News
ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera
The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera (PV).
Lymphoma
Indolent B-Cell Lymphomas
News
Bexobrutideg earns FDA Orphan Drug status in Waldenström macroglobulinemia
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to bexobrutideg (NX-5948), a first-in-class Bruton’s tyrosine kinase (BTK) degrader, for
News
Society Updates
SOHO launches new fundraising initiative
SOHO is launching a special initiative now through its Thirteenth Annual Meeting in Houston, Texas, taking place between September 3 and 6, 2025!
Multiple Myeloma
China NMPA approves IND for KPG-818 in relapsed or refractory MM
The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.
Lymphoma
T-Cell Lymphoma
FDA clears linperlisib for phase 3 trial in relapsed/refractory PTCL
The US Food and Drug Administration (FDA) has approved the design of a global phase 3 trial for linperlisib for the treatment of
Acute Lymphoblastic Leukemia
News
Nanobody-based CD7 CAR-T induces responses in patients with AML in early-phase study
A phase 1 study found that “naturally selected” CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy was well-tolerated and induced complete responses (CRs) in
Society Updates
Ask the lymphoma expert: Dr. Maddocks
Have a burning question about a patient with B-cell malignancies for Hodgkin or non-Hodgkin lymphoma? Ask Kami Maddocks, MD, professor in the College
Cellular Therapy
Lymphoma
News
Risk factors for manufacturing failure, associated outcomes in patients receiving CAR-T for LBCL
Researchers found that prior use of bendamustine within six months of apheresis was the only baseline variable associated with a risk of manufacturing
Cellular Therapy
Multiple Myeloma
Patient case highlights secondary tumor after CAR-T treatment for myeloma
A case study of a 63-year-old male with early relapse of multiple myeloma (MM) indicated that treatment with a chimeric antigen receptor (CAR)